Filing Flows › Axsome Therapeutics (AXSM) › R&D spending
Axsome Therapeutics (AXSM) R&D spending by quarter
Axsome Therapeutics' R&D spending was $50.6M in Q3 2026 (third quarter 2026), +9% from Q2 2026. Over the last 5 quarters it ranged from $40.2M (Q3 2025) to $52.7M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $50.6M | +9% | +26% |
| Q2 2026 | $46.2M | -12% | — |
| Q1 2026 | $52.7M | +31% | +18% |
| Q3 2025 | $40.2M | -10% | — |
| Q1 2025 | $44.8M | — | — |
Q3 2026 at a glance
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Axsome Therapeutics' R&D spending?
Axsome Therapeutics' R&D spending was $50.6M in Q3 2026 (third quarter 2026), +9% from Q2 2026.
How has Axsome Therapeutics' R&D spending changed?
Over the last 5 quarters it ranged from $40.2M (Q3 2025) to $52.7M (Q1 2026).